Cargando…

A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with Extremely Low Warfarin Dose Requirement

We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Soo-Youn, Nam, Myung-Hyun, Kim, June Soo, Kim, Jong-Won
Formato:	Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2007
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693655/ https://www.ncbi.nlm.nih.gov/pubmed/17596671 http://dx.doi.org/10.3346/jkms.2007.22.3.557

Ejemplares similares

A Case of Intolerance to Warfarin Dosing in an Intermediate Metabolizer of CYP2C9
por: Lee, Soo-Youn, et al.
Publicado: (2005)

Extremely Elevated International Normalized Ratio of Warfarin in a Patient with CYP2C9(*)1/(*)3 and Thyrotoxicosis
por: Lee, Ji Eun, et al.
Publicado: (2014)

CYP2C9 Mutation Affecting the Individual Variability of Warfarin Dose Requirement
por: Kim, Young Bum, et al.
Publicado: (2012)

VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
por: Park, Sea Mi, et al.
Publicado: (2013)

Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
por: Haug, Kari Bente Foss, et al.
Publicado: (2008)

Warfarin Dosing in a Patient with CYP2C9(∗)3(∗)3 and VKORC1-1639 AA Genotypes
por: Johnson, Mark, et al.
Publicado: (2014)

The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)

Lack of Association of Clinical Factors (SAMe-TT(2)R(2)) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality
por: Park, Yun Kyung, et al.
Publicado: (2015)

Height, VKORC1 1173, and CYP2C9 Genotypes Determine Warfarin Dose for Pediatric Patients with Kawasaki Disease in Southwest China
por: Yang, Dan, et al.
Publicado: (2018)

The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients’ Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm
por: Khaleqsefat, Esmat, et al.
Publicado: (2020)

CYP2C9*3 polymorphism presenting as lethal subdural hematoma with low-dose warfarin
por: Karnik, Niteen D., et al.
Publicado: (2014)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020)

Determination of Pleiotropic Effect of Warfarin in VKORC1 and CYP2C9 Genotypes in Patients With Heart Valve Replacement
por: Shafique, Huma, et al.
Publicado: (2022)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
por: Shahabi, Payman, et al.
Publicado: (2018)

Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With VKORC1 1173C
por: Cho, Eun Hye, et al.
Publicado: (2020)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

Warfarin Dosing Requirement According to Body Mass Index
por: Alshammari, Abdullah, et al.
Publicado: (2020)

The Impact of CYP2C9*11 Allelic Variant on the Pharmacokinetics of Phenytoin and (S)‐Warfarin
por: Wanounou, Maor, et al.
Publicado: (2022)

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
por: Takeuchi, Fumihiko, et al.
Publicado: (2009)

Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017)

Impact of regular physical activity on weekly warfarin dose requirement
por: Rouleau-Mailloux, Étienne, et al.
Publicado: (2015)

Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2017)

Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report
por: Aldiban, Weam, et al.
Publicado: (2022)

Characterizing variability in warfarin dose requirements in children using modelling and simulation
por: Hamberg, Anna-Karin, et al.
Publicado: (2014)

Correction: Tacrolimus dose requirement based on the CYP3A5 genotype in renal transplant patients
por: Qu, Lihui, et al.
Publicado: (2020)

A PCR method for VKORC1 G-1639A and CYP2C9 A1075C genotyping useful to warfarin therapy among Japanese
por: Tamura, Takashi, et al.
Publicado: (2014)

Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population
por: Hadjipanagi, Despina, et al.
Publicado: (2014)

Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
por: Poopak, Behzad, et al.
Publicado: (2015)

The effect of CYP2C9*2, CYP2C9*3, and VKORC1-1639 G>A polymorphism in patients under warfarin therapy in city of Kermanshah
por: Hosseinkhani, Zohreh, et al.
Publicado: (2018)

Polymorphisms of CYP2C9*2, CYP2C9*3 and VKORC1 genes related to time in therapeutic range in patients with atrial fibrillation using warfarin
por: da Silveira, Maria Mariana Barros Melo, et al.
Publicado: (2019)

A Case Report of a Poor Metabolizer of CYP2D6 Presented with Unusual Responses to Nortriptyline Medication
por: Lee, Soo-Youn, et al.
Publicado: (2004)

Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
por: Syn, Nicholas L., et al.
Publicado: (2018)

Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation
por: Li, Jiao, et al.
Publicado: (2018)

Association between CYP2C9, VORC1, VDR, and APOE genotypes on warfarin maintenance and response during initial anticoagulation for Chinese patients with heart valve replacement
por: Li, Xiaoye, et al.
Publicado: (2022)

Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial
por: Guo, Chengxian, et al.
Publicado: (2020)

Influence of CYP4F2, ApoE, and CYP2A6 gene polymorphisms on the variability of Warfarin dosage requirements and susceptibility to cardiovascular disease in Jordan
por: AL-Eitan, Laith N., et al.
Publicado: (2021)

Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis
por: Jorgensen, Andrea L., et al.
Publicado: (2012)

Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019)

Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis
por: Takeuchi, Masanobu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n7io2k7l7gq45bfv2aq5f80nj5